The randomized trial, called BATON-CRC, will enroll approximately 252 patients with no prior VEGF-targeted therapy at approximately 80 centers in the US, Canada, Australia and Europe, the company said.
Patients will be randomized to one of the two treatments arms in a 2:1 ratio (168 patients in the tivozanib arm and 84 patients in the bevacizumab arm).
AVEO chief medical officer William Slichenmyer said the identification and development of relevant biomarkers through their human response platform is a core component of our oncology drug development efforts.
"We plan to use biomarker data from BATON-CRC and BATON-RCC to inform our clinical development strategy in an effort to bring tivozanib to patients who will benefit most," Slichenmyer added.